Oral anticoagulant and antiplatelet therapy and peripheral arterial disease - Wikidata - awgldk - TriplyDB

Oral anticoagulant and antiplatelet therapy and peripheral arterial disease

Oral anticoagulant and antiplatelet therapy and peripheral arterial disease

http://www.wikidata.org/entity/Q28218519

about

Comparison of central adjudication of outcomes and onsite outcome assessment on treatment effect estimates Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication Antiplatelet agents for intermittent claudication Renal artery stenosis-when to screen, what to stent?Plant Alkaloids as Antiplatelet Agent: Drugs of the Future in the Light of Recent Developments Guidelines on oral anticoagulation with warfarin - fourth edition 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Gu The safety of clopidogrel.Empirical anticoagulation for patients in sinus rhythm at high risk of ischaemic stroke: A review of current literature.Current approach to the diagnosis and treatment of femoral-popliteal arterial disease. A systematic review Peripheral artery disease: current insight into the disease and its diagnosis and management.Peripheral arterial disease: a literature review.Peripheral artery disease and chronic kidney disease: clinical synergy to improve outcomes.Antiplatelet therapy for peripheral arterial disease and critical limb ischemia: guidelines abound, but where are the data?Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Gu Usual blood pressure, peripheral arterial disease, and vascular risk: cohort study of 4.2 million adults A Meta-Analysis of Randomized Controlled Trials on Antiplatelet Agents Versus Placebo/Control for Treating Peripheral Artery Disease.Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.Increased Peripheral Arterial Calcification in Patients Receiving Warfarin Medical management and cardiovascular risk reduction in peripheral arterial disease Oral anticoagulants and non-cardioembolic stroke prevention.Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous?Vitamin K-dependent proteins, warfarin, and vascular calcification The Diagnosis and Treatment of Peripheral Arterial Vascular Disease.Treatment strategies for peripheral artery disease.Residual risk for secondary ischemic events in patients with atherothrombotic disease: opportunity for future improvements in patient care.A review of simple, non-invasive means of assessing peripheral arterial disease and implications for medical management.Carotid artery disease and stenting: insights from recent clinical trials.Peripheral artery disease. Part 2: medical and endovascular treatment.What information should a sponsor of a randomized trial receive during its conduct?Preventive aspects in peripheral artery disease.Thrombin inhibition by dabigatran attenuates atherosclerosis in ApoE deficient mice.Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside.Current therapies and investigational drugs for peripheral arterial disease.Antithrombotic therapy in peripheral artery disease.Medical Therapy in Peripheral Artery Disease and Critical Limb Ischemia.2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.Unmet Needs in Anticoagulant Therapy: Potential Role of Rivaroxaban.

P2860

Q24186056-7DA26070-40A9-4717-BA9A-2AEBA78B5ADC Q24194752-8B4C1D0B-FAE2-4DA8-808E-B066BB4B5DC8 Q24235178-8E2F09FA-D9EA-45E2-B39F-173B6B2B067E Q26829330-7C6A4212-C6C7-46B9-A744-DF430EE4BED1 Q28076248-2A409674-0548-48D9-BFDA-18DD079A1E82 Q28240666-81A7A943-7476-4170-8BB2-97CDE7290077 Q28249469-DC71C9C9-354E-49AA-B8E0-54F5B00DF449 Q33392895-8BEDA4ED-1292-4B34-8F0E-E7F4A7A296AF Q33721188-D314F387-AF55-4417-BEAD-B60DFA383F85 Q33743880-BFD4346F-DEE8-4166-AA8D-FC8542A8A8AF Q33951581-BFA8ACC6-2108-44E0-B0A7-410601AD4745 Q34451668-C2917C7B-E1CC-4E65-B991-BC6EE5741346 Q34625055-63A994F0-43F3-4607-835A-48EEDA92166A Q35216396-D35713E2-B946-4998-8075-D0AAFA0A28D9 Q35752591-613C0425-883F-4FFC-99D3-57869A774393 Q35860891-74CC0FEA-A996-4976-8B84-7ABD0E16656F Q36101890-186CD8E8-E4FB-4702-AF40-746C927BBAC2 Q36194774-BD8EC31E-497A-424D-9B09-3031DD9ECB89 Q36316309-BBBC5A43-38E3-4575-89EB-7E6FFDC02DD1 Q36877718-71463565-DA49-4DB8-962F-8323D26F0076 Q36981330-EF56BE90-5D40-472A-8192-7FDE7A03BEA7 Q37121384-D454746C-FE3F-4DB0-B6DE-D3A0ADB135B1 Q37162895-C5D46EA4-51D0-4E64-B11A-2F54E29DD519 Q37170124-1006E3E6-9889-4AAD-A824-17834F87193E Q37492857-566A2B62-0D41-4276-887E-5D186084B695 Q37519704-5C251998-017B-4F99-9DB5-5466D2B25E89 Q37679209-04854D68-491B-4674-9113-DBDEADF3370D Q37692405-345153C9-613A-4ECD-B088-E496B288DDED Q37841251-20EFC40F-9951-4122-AD25-42B637025317 Q37889106-954E2EC3-F2C1-4C35-909C-C2F9CC247F68 Q37949094-87791BB2-EF5C-48DF-8DEC-8C02C2D5007D Q37984281-3BC441CE-BDC0-4649-8781-388E3E933EE4 Q38271983-A874BE8D-E2B0-47AB-A7B7-1E34DDED3D22 Q38402334-2A764A0F-538C-40B7-8B1F-A1083C5D5778 Q38657444-C20721CF-2D82-4E8E-8601-7B3265D1BF53 Q38715643-4865E80A-A8ED-48BB-815A-BE388612DCF7 Q38834990-256FD12A-5368-4ED2-90D5-7ECC980CF637 Q39007230-C691C2BB-670D-43D9-893F-FFA7EC5A0191 Q39007236-1E0A5BC9-0CF5-431D-BFA1-BE9A573A9AF2 Q39135634-8DAF744A-A441-43B4-91DF-651D57EDBAF9

P2860

Oral anticoagulant and antiplatelet therapy and peripheral arterial disease

http://www.wikidata.org/entity/Q28218519

description

2007 nî lūn-bûn

@nan

2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Oral anticoagulant and antiplatelet therapy and peripheral arterial disease

@ast

Oral anticoagulant and antiplatelet therapy and peripheral arterial disease

@en

Oral anticoagulant and antiplatelet therapy and peripheral arterial disease

@nl

type

label

Oral anticoagulant and antiplatelet therapy and peripheral arterial disease

@ast

Oral anticoagulant and antiplatelet therapy and peripheral arterial disease

@en

Oral anticoagulant and antiplatelet therapy and peripheral arterial disease

@nl

prefLabel

Oral anticoagulant and antiplatelet therapy and peripheral arterial disease

@ast

Oral anticoagulant and antiplatelet therapy and peripheral arterial disease

@en

Oral anticoagulant and antiplatelet therapy and peripheral arterial disease

@nl

P1433

Q28218519-791380BD-EF1F-4C04-A4EA-A1CE87240EDB

P1476

Q28218519-856CD1D2-B136-4C4C-BF14-77F412F1489F

P2093

Q28218519-0BD86493-B487-4EA7-B92F-63D272614850

Q28218519-1783EED8-2077-4570-B86B-856A03EBBDAF

Q28218519-1896435A-A7C6-40A8-9C27-044F45C26556

Q28218519-76500CD0-EBEF-41B9-9FA3-E9924480E11C

Q28218519-9A80C583-3913-4CE0-AF96-158D7E9E2C8C

Q28218519-9B920BEF-B28A-4AF6-9BA1-CAF0E4EED81D

Q28218519-C03CB10C-E232-4872-9B9B-9D6B270E6C25

Q28218519-E11E2770-1322-4A02-980C-9A40D8394FE0

Q28218519-F4762A66-BD79-4114-AE81-B45E91136A2F

P304

Q28218519-9E43FC90-CD49-4D19-82CA-E3723A12A70D

P31

Q28218519-7D982A8E-B8F1-40CB-9D72-4A8848E8E880

P3181

Q28218519-9C73BE94-7140-4C26-B2B9-9DA6843CAB98

P356

Q28218519-B22937E0-2204-4BE9-A282-6A56A17DE9B7

P407

Q28218519-DB1456BF-43BB-40BF-B74C-6C182752A59E

P433

Q28218519-A985A666-95A2-4BEF-83DE-73C0A8806DB9

P478

Q28218519-73055B79-97DA-4DA7-878F-515DCAA58C3C

P50

Q28218519-1E8015A9-B9B2-4DD1-9467-0F54C24A3CBB

Q28218519-B4EA1A5B-2FFF-4BB4-9794-57257D1DD7F9

Q28218519-C26A1B4C-AFCC-4323-A835-7EB9CB329F29

Q28218519-C75F0298-D062-42CC-B04A-1593295FEC76

Q28218519-F1C2B868-AFBF-48E4-B5D7-59AD72E93ABB

P577

Q28218519-C04B74C2-D8D4-4398-A3E5-7B6B99145520

P698

Q28218519-7AA8FDE1-4727-4490-9007-34E769905890

P921

Q28218519-589136CA-AD84-446B-9BAA-FD873CD4ADD1

P3181

P356

P1433

The New England Journal of Medicine

P1476

Oral anticoagulant and antiplatelet therapy and peripheral arterial disease

@en

P2093

Bruce Sussex

http://www.w3.org/2001/XMLSchema#string

Changchun Xie

http://www.w3.org/2001/XMLSchema#string

Claudio Cina

http://www.w3.org/2001/XMLSchema#string

Gilbert Gosselin

http://www.w3.org/2001/XMLSchema#string

Lisheng Liu

http://www.w3.org/2001/XMLSchema#string

Matyas Keltai

http://www.w3.org/2001/XMLSchema#string

Richard Crowell

http://www.w3.org/2001/XMLSchema#string

Sonia Anand

http://www.w3.org/2001/XMLSchema#string

Warfarin Antiplatelet Vascular Evaluation Trial Investigators

http://www.w3.org/2001/XMLSchema#string

P304

217-227

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3382532

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA065959

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

357

http://www.w3.org/2001/XMLSchema#string

P50

John W. Eikelboom

Randolph P Guzman

P577

2007-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17634457

http://www.w3.org/2001/XMLSchema#string

P921

anticoagulation